Bringing the Oncology Community Together

Maximum 12-Month Follow-Up Suffices in More than Half of Men with Surgically-Treated Invasive Penile Cancer

In men with primary squamous cell carcinoma of the penis who have undergone surgery that removed all glanular epithelium a maximum 12-month follow-up period is recommended.

Urologists in Cancer Care   >   Conference Highlights

A Word of Welcome

It is with great pleasure that I welcome you to the inaugural issue of Urologists in Cancer Care.

Urologists in Cancer Care   >   From the Editor

Battling the Odds in RCC: Interview With Brian Rini, MD

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

Oncology Live   >   Profiles in Research

National Comprehensive Cancer Network: Beyond the Treatment Guidelines

Each year at its annual meeting, the National Comprehensive Cancer Network presents updates to its Clinical Practice Guidelines in Oncology.

OncLive Nursing   >   Nurse's Notes

Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Oncology Live   >   Clinical Insights

Support for Dose Titration of Axitinib in AXIS Trial Results

The concept of dose titration in patients with mRCC who fail to achieve therapeutic levels on axitinib was validated by a secondary analysis.

Oncology & Biotech News   >   Conference Highlights

Chemotherapy-Related Fatigue Persists Over Time

Patients who undergo chemotherapy for breast cancer may develop fatigue that remains problematic long after they complete treatment.

Oncology & Biotech News   >   Clinical Trial Reports

FDA Approves Axitinib for Advanced Kidney Cancer Patients

The FDA approved axitinib for the treatment of patients with advanced RCC who have failed to respond to another drug.

  >   Web Exclusives

Axitinib Nears Approval as Second-Line Therapy for Metastatic Renal Cell Carcinoma

Axitinib has shown promising results in phase II and III trials, including the AXIS trial in patients with metastatic clear cell RCC who failed on other treatments.

Oncology & Biotech News   >   Conference Highlights

Tivozanib Demonstrates Better PFS Than Sorafenib, but Failed to Meet Investors Expectations

The investigational drug, tivozanib, showed improved rates of PFS in patients with advanced RCC than the already-approved sorafenib.

  >   Web Exclusives

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

  >   Web Exclusives

November 2011: Trials in Progress

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

Oncology & Biotech News   >   Clinical Trial Reports

Tumoral CRP Levels Correlate With Survival in Renal Cell Carcinoma

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.

Oncology Live   >   Specialty Focus

Treatment Guidelines for High-Grade Bladder Cancer Are Usually Ignored

Investigators have documented gross under-use of established recommendations for the management of high-grade noninvasive bladder cancer.

Oncology & Biotech News   >   Clinical Trial Reports

Link Found Between Long-Term Nonaspirin NSAIDs and Renal Cell Carcinoma

The use of nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs) is associated with an increased risk of renal cell carcinoma (RCC).

Oncology & Biotech News   >   Clinical Trial Reports

3 ASCO Updates Tackle Treatment and Supportive Care Questions

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Oncology Live   >   Features

Expanding the Scope of Cystoscopy: Imaging Agent Illuminates More Lesions

An interview with Neal D. Shore, MD, discussing expanding the scope of cystoscopy and the optical imaging agent Cysview.

Oncology Live   >   TechSectors

ASCO Highlights: Trials in Progress

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Oncology & Biotech News   >   Conference Highlights

FDA Advised Not to Approve Dapagliflozin for Diabetes

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.

  >   Web Exclusives

5 Abstracts Offer Snapshot of Immunology Research

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

Oncology Live   >   Features